QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
NASDAQ:SCYX

SCYNEXIS (SCYX) Stock Forecast, Price & News

$2.59
+0.05 (+1.97%)
(As of 06/8/2023 ET)
Compare
Today's Range
$2.48
$2.61
50-Day Range
$2.38
$3.67
52-Week Range
$1.15
$3.84
Volume
404,750 shs
Average Volume
1.16 million shs
Market Capitalization
$94.59 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.50

SCYNEXIS MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
305.4% Upside
$10.50 Price Target
Short Interest
Healthy
4.52% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From $0.51 to ($0.45) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.81 out of 5 stars

Medical Sector

700th out of 986 stocks

Pharmaceutical Preparations Industry

325th out of 473 stocks


SCYX stock logo

About SCYNEXIS (NASDAQ:SCYX) Stock

SCYNEXIS, Inc., a biotechnology company, develops products for the treatment of fungal infections in the United States. It offers BREXAFEMME for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of various fungal infections, including invasive candidiasis, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

Receive SCYX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SCYNEXIS and its competitors with MarketBeat's FREE daily newsletter.

SCYX Stock News Headlines

Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
SCYNEXIS: Q1 Earnings Insights
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
Scynexis: Q1 Earnings Snapshot
SCYNEXIS, Inc. (NASDAQ:SCYX) Short Interest Update
SCYNEXIS (NASDAQ:SCYX) Downgraded by StockNews.com to Sell
SCYNEXIS (NASDAQ:SCYX) Stock Rating Upgraded by StockNews.com
SCYNEXIS (SCYX) Receives a Buy from Ladenburg Thalmann & Co.
Scynexis (SCYX) Inks Antifungal Drug Deal With GSK
See More Headlines

SCYX Price History

SCYX Company Calendar

Last Earnings
3/31/2023
Today
6/08/2023
Next Earnings (Estimated)
8/21/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SCYX
Employees
36
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.50
High Stock Price Forecast
$15.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+303.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-62,810,000.00
Net Margins
-1,648.61%
Pretax Margin
-1,648.61%

Debt

Sales & Book Value

Annual Sales
$5.09 million
Book Value
$0.10 per share

Miscellaneous

Free Float
34,925,000
Market Cap
$94.95 million
Optionable
Optionable
Beta
2.13

Key Executives

  • Mr. David Gonzalez Angulo M.D. (Age 58)
    CEO, Pres & Director
    Comp: $631.69k
  • Mr. Scott Sukenick J.D. (Age 45)
    Chief Legal Officer & Corp. Sec.
    Comp: $542.05k
  • Mr. Ivor Macleod CPA (Age 62)
    M.B.A., Chief Financial Officer
  • Debbie Etchison
    Exec. Director of Communications
  • Ms. Daniella Gigante
    VP of HR













SCYX Stock - Frequently Asked Questions

Should I buy or sell SCYNEXIS stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for SCYNEXIS in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SCYX shares.
View SCYX analyst ratings
or view top-rated stocks.

What is SCYNEXIS's stock price forecast for 2023?

3 Wall Street research analysts have issued 1-year target prices for SCYNEXIS's shares. Their SCYX share price forecasts range from $8.00 to $15.00. On average, they predict the company's share price to reach $10.50 in the next twelve months. This suggests a possible upside of 303.8% from the stock's current price.
View analysts price targets for SCYX
or view top-rated stocks among Wall Street analysts.

How have SCYX shares performed in 2023?

SCYNEXIS's stock was trading at $1.56 at the start of the year. Since then, SCYX shares have increased by 66.7% and is now trading at $2.60.
View the best growth stocks for 2023 here
.

When is SCYNEXIS's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our SCYX earnings forecast
.

How were SCYNEXIS's earnings last quarter?

SCYNEXIS, Inc. (NASDAQ:SCYX) announced its quarterly earnings data on Friday, March, 31st. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.50) by $0.21. The business had revenue of $1.52 million for the quarter, compared to analyst estimates of $1.28 million. SCYNEXIS had a negative net margin of 1,648.61% and a negative trailing twelve-month return on equity of 875.77%.

When did SCYNEXIS's stock split?

Shares of SCYNEXIS reverse split on the morning of Friday, July 17th 2020. The 1-10 reverse split was announced on Thursday, July 16th 2020. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 16th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of SCYNEXIS own?
What is SCYNEXIS's stock symbol?

SCYNEXIS trades on the NASDAQ under the ticker symbol "SCYX."

Who are SCYNEXIS's major shareholders?

SCYNEXIS's stock is owned by a number of institutional and retail investors. Top institutional investors include Kingdon Capital Management L.L.C. (4.10%), AIGH Capital Management LLC (3.17%), Stonepine Capital Management LLC (1.23%), BlackRock Inc. (1.04%), D.A. Davidson & CO. (0.91%) and AMH Equity Ltd (0.75%). Insiders that own company stock include Brian Philippe Tinmouth, Eric Francois, Marco Taglietti, Perceptive Advisors Llc and Scott Sukenick.
View institutional ownership trends
.

How do I buy shares of SCYNEXIS?

Shares of SCYX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is SCYNEXIS's stock price today?

One share of SCYX stock can currently be purchased for approximately $2.60.

How much money does SCYNEXIS make?

SCYNEXIS (NASDAQ:SCYX) has a market capitalization of $94.95 million and generates $5.09 million in revenue each year. The company earns $-62,810,000.00 in net income (profit) each year or ($1.93) on an earnings per share basis.

How can I contact SCYNEXIS?

SCYNEXIS's mailing address is 1 EVERTRUST PLAZA 13TH FLOOR, JERSEY CITY NJ, 07302. The official website for the company is www.scynexis.com. The company can be reached via phone at (201) 884-5485, via email at ikoffler@lifesciadvisors.com, or via fax at 201-884-5490.

This page (NASDAQ:SCYX) was last updated on 6/8/2023 by MarketBeat.com Staff

My Account -